Session Information
-
WCLC 2021
2021 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
All times listed are in Mountain Time MDT (UTC-6:00)
PL - Plenary
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
WS - Workshops
IS - Industry Symposium
MTE - Meet the Expert
BEDG - Brain Exchange Discussion Groups
September 8 Wed
Sep 8 Thursday
September 9 Thu
Sep 9 Friday
September 10 Fri
Sep 10 Saturday
September 11 Sat
Sep 11 Sunday
September 12 Sun
Sep 12 Monday
September 13 Mon
Sep 13 Tuesday
September 14 Tue
Sep 14
-
+
MA04 - Current Status and Future Prospects of Pleural Mesothelioma and Thymoma
- 10:45 - 11:45
- 9/08/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Mesothelioma, Thymoma and Other Thoracic Malignancies
-
+
MA04.03 - A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor (KCSG LU17-21)
10:55 - 11:00 | Presenter: Hyun Ae Jung
- Abstract
Loading...
-
+
FP16 - Tumor Biology and Systems Biology: Basic and Translational Science
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters (Featured)
- Track: Tumor Biology and Systems Biology: Basic and Translational Science
-
+
FP16.03 - Early Circulating-Tumor DNA EGFR Mutation Clearance in Plasma as a Predictor of Clinical Outcomes in The AURA3 Trial
00:00 - 00:00 | Presenter: Myung-Ju Ahn
- Abstract
Loading...
-
+
P15 - Immunotherapy (Phase II/III Trials) - Early Stage NSCLC
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P15.01 - Phase II Prospective Study of Adjuvant Pembrolizumab in N2 Positive NSCLC Treated With Neoadjuvant CCRT Followed by Surgery
00:00 - 00:00 | Presenter: Sehhoon Park
- Abstract
Loading...
-
+
P45 - Novel Therapeutics and Targeted Therapies - ALK/ROS1/MET
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
-
+
P45.06 - Overall Survival From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1+ Advanced Non-Small-Cell Lung Cancer
00:00 - 00:00 | Presenter: Yi-Long Wu
- Abstract
Loading...
-
+
P47 - Novel Therapeutics and Targeted Therapies - Clinical Trial in Progress
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
-
+
P47.08 - A Phase II, Single-arm, Multicenter, Efficacy of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC
00:00 - 00:00 | Presenter: Sehhoon Park
- Abstract
Loading...
-
+
IS08 - Industry Symposium Sponsored by Eli Lilly And Company: Personalizing and Optimizing Treatment for Metastatic NSCLC Patients with EGFR Mutations - Is There More We Can Do?
- 05:45 - 06:45
- 9/10/2021
- Location: Industry Symposium Auditorium via Industry Hub
- Not for CME Credit
- Type: Industry Supported Symposium
- Track: N.A.
-
+
IS08.04 - Identifying the Clinical and Disease Characteristics of the High Risk Patient, What Is the Science Telling Us?
06:15 - 06:25 | Presenter: Myung-Ju Ahn
- Abstract
No abstract available for this presentation
-
+
MA13 - Building on the Past: What Will Be the Next Immunotherapy Combination?
- 17:30 - 18:30
- 9/13/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Immunotherapy (Phase II/III Trials)
-
+
MA13.03 - Combination of Bevacizumab + Atezolizumab (A) Who Progressed On A In Pretreated NSCLC Patients: An Open-Label, Two-Stage, Phase II Trial
17:40 - 17:45 | Presenter: Jiyun Lee
- Abstract
Loading...
-
+
ES20 - Caveats, Challenges, and Controversies in Immunotherapy of Lung Cancer: Phase II and Phase III Trials*
- 20:30 - 21:05
- 9/14/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Education Session
- Track: Immunotherapy (Phase II/III Trials)
*Full-length Educational talk will be available as pre-release content as of September 1. The Live Day Educational Sessions will feature brief summaries and extended live discussion with the presenters. Delegates are encouraged to watch the pre-released content prior to watching the live Educational Sessions.- Moderators:David R. Gandara, Myung-Ju Ahn
-
+
ES20.01 - The Statistical Imperatives of Immunotherapy Research
20:30 - 20:32 | Presenter: Mary Redman
- Abstract
No abstract available for this presentation
-
+
ES20.02 - Charting a New Path: Defining Better Endpoints in Immune Therapy Trials in Lung Cancer
20:32 - 20:34 | Presenter: Sanjay Popat
- Abstract
Loading... -
+
ES20.03 - Open and Unanswered Questions for Treatment and Needed Studies: What We Do and Do Not Know
20:34 - 20:36 | Presenter: Nick Pavlakis
- Abstract
No abstract available for this presentation
-
+
ES20.04 - Challenges to Expand Who Gets Immunotherapy
20:36 - 20:38 | Presenter: Lyudmila Bazhenova
- Abstract
No abstract available for this presentation
-
+
ES20.05 - Live Discussion with Speakers
20:38 - 21:05
- Abstract
No abstract available for this presentation
